The Global Cancer Immunotherapy Market achieved a valuation of $121.2 Billion in 2023 and is anticipated to exceed $245.37 ...

TuHURA Biosciences, a biotech firm, is advancing DNA-based immunotherapy for cancer. Read what warrants a Hold rating for ...

UniSA Professor Richard D'Andrea and Associate Professor Lisa Ebert in the new lab.A new tissue culture facility has opened at UniSA today, helping to ...

The BC Cancer Foundation has launched a $6.8 million fundraising campaign to expand provincial immunotherapy research program ...

The American Society for Transplantation and Cellular Therapy® (ASTCT®) is pleased to announce David L. Porter, MD, as the ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

A retrospective analysis showed improved overall survival (OS) with Orca-T compared with post-transplant cyclophosphamide in ...

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood ...

Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable ...

CHICAGO, ILLINOIS / ACCESS Newswire / February 17, 2025 / The American Society for Transplantation and Cellular Therapy® ...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, ...

Preparations for pivotal-stage readiness of vididencel in AML on trackThe hard work of the Mendus team to advance the company's lead product vididencel in acute myeloid leukemia (AML) continued to pay ...